Effects of MDR1 and OPRM1 genetic polymorphisms on the pharmacodynamics of propofol-remifentanil TIVA in pediatrics

Pharmacogenomics. 2023 Apr;24(5):247-259. doi: 10.2217/pgs-2023-0006. Epub 2023 Mar 31.

Abstract

Aims: To investigate the roles of MDR1 (1236C>T, 2677G>T/A, and 3435C>T) and OPRM1 (118A>G) gene polymorphisms on the anesthetic and adverse effects of propofol-remifentanil total intravenous anesthesia in pediatric surgery. Materials & methods: The genotypes were identified through Sanger sequencing. The clinical data including hemodynamics on anesthesia, postanesthesia pain and sedation score and the occurrence of adverse effects were recorded and compared against the genetic data. Results: A total of 72 pediatric patients undergoing surgery were recruited. A weak to no association was found between the genetic polymorphisms of MDR1 and OPRM1 and the anesthetic and adverse effects of propofol-remifentanil. Conclusion: Genetic polymorphisms in OPRM1, but not in MDR1, gene polymorphism, demonstrated plausible association with the effects of propofol-remifentanil.

Keywords: MDR1; OPRM1; anaesthesia; analgesia; genetic polymorphism; paediatrics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anesthetics, Intravenous / adverse effects
  • Child
  • Humans
  • Piperidines / adverse effects
  • Polymorphism, Genetic
  • Propofol* / adverse effects
  • Receptors, Opioid, mu / genetics
  • Remifentanil

Substances

  • Anesthetics, Intravenous
  • OPRM1 protein, human
  • Piperidines
  • Propofol
  • Receptors, Opioid, mu
  • Remifentanil
  • ABCB1 protein, human